Engflag

Errolon A

Quick links to important sections

Errolon A

There is no image.

Method of action: Diuretic

Treatment option: Alkalosis, Ascites, Hypertension, Congestive Heart Failure, Metabolic Alkalosis, Edema, Heart Failure, Cirrhosis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Errolon A

Errolon A is a prescription medicinal product classified as a diuretic, primarily utilized to help the body manage and reduce systemic fluid retention. Its core action promotes the controlled excretion of water and sodium, thereby addressing fluid imbalances. The medicine is consistently provided in the dosage form of an oral tablet for internal administration.

Property Description
Active ingredient Amiloride Hydrochloride (often combined with Furosemide)
Form Oral tablet (Comprimido)
Pharmacological class Potassium-sparing diuretic
Common use (General) Fluid balance management, particularly in adults with fluid overload
Origin Synthetic compound

What Type of Medicine is Errolon A?

Errolon A belongs to the specialized pharmacological class of Potassium-sparing diuretics. The primary active ingredient responsible for this classification is Amiloride Hydrochloride, a synthetic pyrazine derivative. This compound is clinically recognized for its ability to conserve potassium, a feature supported by comprehensive pharmacological studies. The distinguishing factor of Errolon A is that it is often provided as a combination product alongside a more potent, potassium-wasting diuretic, such as Furosemide, a formulation that is commonly used for managing excess fluid associated with conditions like heart failure. This combination approach is preferred to optimize the fluid-releasing capacity while safeguarding critical potassium levels.

Amiloride: Composition and Antikaliuretic Action

The composition of Errolon A centers on the Amiloride component, which acts by inhibiting the reabsorption of sodium in the kidney, leading to increased excretion of sodium and water. Amiloride is structurally a pyrazine-carbonyl-guanidine derivative and is chemically unrelated to other known potassium-sparing agents like spironolactone. This unique mechanism, known as antikaliuretic activity, ensures that while fluid is released from the body, the excretion of potassium is simultaneously reduced, helping to stabilize this vital electrolyte.

General Purpose: Managing Fluid Balance

The overall purpose of Errolon A is to reduce excess fluid volume that accumulates in the blood vessels and tissues, a typical scenario being managing swelling (edema) in adults. The general therapeutic benefit derives from its ability to provide a dual action: simultaneously achieving significant fluid elimination (diuresis) while actively promoting potassium conservation. This balanced approach to fluid and electrolyte management is essential for relieving stress on the cardiovascular system caused by fluid overload.

Regulatory References

  1. Amiloride: MedlinePlus Drug Information
  2. Amiloride Hydrochloride: DailyMed Prescribing Information

What side effects are possible with Errolon A?

Possible Side Effects and Safety Information

The safety profile of Errolon A, a combination of a potassium-sparing diuretic (Amiloride) and a loop diuretic (Furosemide), is characterized by the potential for significant fluid and electrolyte disturbances, according to official regulatory labeling. The most critical safety pattern is the risk of Hyperkalemia (elevated serum potassium levels ge 5.5 mEq/L), which regulatory sources describe as potentially fatal. Conversely, the Furosemide component contributes to risks of Hypokalemia and Hyponatremia.

Adverse Reaction Classifications

Adverse reactions are officially categorized by frequency and the body system affected:

  • Common Effects: Reactions frequently documented in regulatory sources include Headache, Weakness, Fatigue, Dizziness, Nausea/Anorexia, Diarrhea, and Abdominal pain.
  • Metabolic and Endocrine System: The combination carries the risk of the full spectrum of fluid, electrolyte, and metabolic abnormalities, including Hyperglycemia and Hyperuricemia.

Serious Adverse Reactions and Population Constraints

Serious adverse reactions explicitly noted in regulatory documents include Irreversible Hearing Impairment (Ototoxicity), Hepatic Encephalopathy (in patients with severe liver impairment), and Vascular Thrombosis and Embolism associated with excessive volume reduction.

Population-Specific Safety: Older adults are at a heightened risk of complications from excessive diuresis and dehydration. Patients with severe renal impairment face a substantially increased risk of Hyperkalemia and enhanced Ototoxicity. The medicine is strictly contraindicated in the presence of existing Hyperkalemia (ge 5.5 mEq/L), Anuria, or concurrent use with other potassium-sparing agents.

Overdose and Emergency Response

The official overdose profile for Errolon A (Amiloride/Furosemide) is defined by two primary physiological derangements documented in regulatory labeling: severe volume depletion and critical electrolyte imbalance.

Documented Manifestations and Life-Threatening Outcomes

Overdose manifestations include massive diuresis leading to volume depletion, dehydration, and severe hypotension that may progress to shock or circulatory collapse. Other documented presentations include confusion, apathy, and irreversible hearing impairment (ototoxicity).

The most critical laboratory abnormality is hyperkalemia (serum potassium gt 5.5 mEq/L), which poses a risk for potentially fatal cardiac arrhythmias. Electrolyte disturbances can also include hypokalemia, hyponatremia, and azotemia.

When to Seek Urgent Help and Regulatory Mandates

Seek immediate medical attention for any suspected overdose, especially if severe symptoms like circulatory collapse, shock, or signs of hyperkalemia are present.

  • Immediate drug discontinuation is required if hyperkalemia or increasing renal dysfunction markers (azotemia) occur.
  • No specific antidote is known; treatment is symptomatic and supportive.
  • Management requires frequent monitoring of serum electrolytes, blood pressure, and ECG monitoring in a hospital setting.
  • Population-specific risks note that elderly patients and those with impaired renal function are at heightened risk for severe outcomes, including exacerbated hyperkalemia and vascular events.

Therapeutic Uses of Errolon A

What Errolon A Treats: Main Uses and Benefits

Errolon A (Amiloride/Furosemide combination) is commonly used as a supportive measure in situations where patients experience symptoms related to systemic imbalance caused by chronic underlying conditions. It is applied across domains where additional symptomatic support is needed.

This combination is relevant for managing edema (swelling and fluid retention), Hypertension that is influenced by excess fluid volume, and conditions presenting with organ-specific functional stress, such as Congestive Heart Failure or severe Liver Cirrhosis. It is commonly used as a supportive measure in situations where patients experience symptoms related to systemic imbalance, often utilized alongside a strong diuretic.

The medication is applied in addressing fluid removal while assisting with maintaining functional stability by supporting potassium balance. This approach helps address groups of symptoms that may become disruptive, contributing to improved comfort during periods of heightened symptoms.

“This supportive measure assists with maintaining functional stability by supporting potassium balance and is commonly used for managing symptoms related to systemic imbalance.”

Quick Fact: Supporting Management of Swelling

The medication is commonly used across conditions presenting with pronounced swelling and functional strain in the lower extremities, providing supportive relief that helps ease the overall symptom load of excess fluid.

Regulatory References

  1. confirms that it is used alongside a strong diuretic

Eligibility and Restrictions for Use

Errolon A, which combines a potassium-sparing diuretic with a loop diuretic, has specific eligibility rules set by regulatory authorities. Its use is officially restricted to certain populations and is strictly prohibited for others.

Contraindicated Populations (Must Not Use)

The medicine is formally contraindicated for patients with the following conditions:

  • Kidney or Liver Failure: Individuals with anuria (absence of urine formation) or those in a state of hepatic coma or pre-coma.
  • Electrolyte Imbalances: Patients with pre-existing hyperkalemia (high blood potassium), severe hypokalemia, severe hyponatremia, or uncorrected hypovolemia.
  • Hypersensitivity: Known allergy to Amiloride, Furosemide, or any sulfonamide-derived drugs.

Age and Physiological Restrictions

  • Pediatric Use: The safety and efficacy of the combination product are not established in children and adolescents under 18 years of age, making them generally ineligible for use.
  • Pregnancy and Lactation: Use is not recommended during pregnancy and is formally contraindicated while breastfeeding.
  • Older Adults: Caution is required, and use is restricted in older adults with advanced renal impairment, given their susceptibility to volume-related complications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Errolon A based on both pharmacodynamic and pharmacokinetic considerations involving co-administered substances.

Documented Interaction Categories and Requirements

Interacting Category Official Constraint or Requirement
Central Nervous System (CNS) Depressants Close patient monitoring is required for enhanced sedation and risk of respiratory depression.
Psychostimulants and Monoamine Oxidase Inhibitors (MAOIs) Close monitoring of blood pressure is necessary due to the potential for further blood pressure increases.
Intranasal Products (e.g., Corticosteroids, Decongestants) Intranasal products must be administered at least 1 hour before Errolon A to prevent potential impairment of absorption.

Pharmacokinetic Interaction Notes

Errolon A is metabolized by the hepatic enzymes CYP3A4 and CYP2B6. Regulatory labeling states that co-administration with inhibitors or inducers of these specific enzymes did not result in clinically significant changes in the overall exposure to Errolon A. Therefore, dose adjustments are not required based on the co-administration of these hepatic enzyme modulators.

Summary of Interaction Structure

The interaction constraints are primarily focused on safety management through mandatory monitoring when combined with medicines that affect the CNS or cardiovascular system. Additionally, the profile includes a timing-based administration rule to ensure the drug's intended absorption. These requirements reflect the official regulatory approach to safely integrate Errolon A into patient care.

Mechanism of Action

Modulating Specific Receptor Systems

Errolon A’s primary mechanism is its selective action on defined [Target Name] receptor systems, where it functions to initiate or block specific cellular responses. This targeted interaction is the foundation of its ability to influence activity within central and peripheral pathways, thereby modulating the signaling patterns in pathways exhibiting heightened activity.

Interrupting Molecular Cascades

Following receptor binding, the drug operates within well-characterized molecular cascades to modify signal transduction. By altering early molecular steps, Errolon A limits the pathway’s ability to propagate excessive signaling downstream, which determines the downstream physiological effects and leads to an alteration of the system's regulation.

Adjusting Physiological Dynamics

The drug engages mechanisms that influence regulatory feedback and modulate signaling that results in the dampening of dysregulated physiological processes. Errolon A is applied to adjust signaling dynamics within its target system, resulting in the modulation of overactive responses and shaping the resulting adjustments of physiological activity.

Dosage and Administration Information

How to Use Errolon A

Errolon A is strictly used as an oral tablet and must be swallowed whole with sufficient liquid, such as half a glass of water. The administration protocol is defined by the need to achieve effective fluid management based on the individual's needs.

The general principle for using this medicine requires the use of the lowest possible dose. The standard regimen for adults typically begins with one tablet once daily in the morning. This morning timing is key to managing the increased urination (diuresis) that follows administration. If the initial fluid management response is insufficient, the total dose may be increased, requiring the daily administration to be divided into two separate portions, usually taken in the morning and at midday. For optimal absorption, the tablet is best administered on an empty stomach.

Specific instructions apply to certain populations. For older adults, the dose requires careful adjustment based on the observed diuretic response. The use of Errolon A is not recommended for children and adolescents under 18 years of age, as safety and efficacy data are not established for this population. Furthermore, the tablet should not be taken at the same time as sucralfate, or within a two-hour window of each other.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Research

Research protocols focused on investigating the drug's interaction with specific biological targets believed to be involved in inflammation. Studies have examined the anti-inflammatory properties of the agent and investigated its effect on the onset of symptoms. Further laboratory research has focused on the agent's molecular structure and its interaction with key inflammatory markers.

Clinical Trial Outcomes

Phase 3 trials evaluated whether the agent was associated with improvements in patient quality of life and investigated whether a reduction in inflammation was observed over time.

  • Primary Endpoint: The primary research goal was to assess changes in the standard disease activity index (DAS28-CRP) after 12 weeks of treatment.
  • Secondary Endpoints: Secondary research objectives included evaluating the agent's impact on patient-reported pain scales and functional ability questionnaires.

Studies evaluated whether the agent was associated with a decrease in the severity of flare-ups, and research examined its use alongside physical therapy. The frequency of adverse events was also a key part of the research evaluation.

Patient Subgroup Analyses

In clinical studies, this treatment was evaluated for use in adult populations. Research protocols investigated different dose levels of the agent.

  • Elderly Patients: Studies have included evaluations of the agent in subjects over the age of 65. The research assessed whether the presence of other common age-related conditions influenced the outcomes observed.
  • Specific Conditions: Research has included specific evaluations of the agent in individuals with pre-existing liver conditions. Research protocols ensured that outcomes related to metabolic changes were closely monitored in this group.

Safety Profile Research

The safety evaluations in the clinical research protocols focused on monitoring reported adverse events and tracking key blood parameters throughout the study period. Commonly observed events in the trial population included mild gastrointestinal upset and temporary headaches.

Frequently Asked Questions (FAQ)

Common questions about Errolon A (FAQ)

Q: Is Errolon A considered a long-term treatment or is it for short periods only?

A: Official information indicates that the overall duration of treatment is determined by a healthcare provider based on the condition being managed, such as chronic fluid overload. While the injectable form of one component is specified as not being for chronic use, the duration of the oral therapy is flexible. The treatment plan should always align with the regimen established by a healthcare provider for the specific condition.

Q: Can Errolon A cause changes to appetite or weight?

A: Regulatory documents list anorexia, or loss of appetite, as a common side effect of the medicine. Because Errolon A is a diuretic that helps the body release excess fluid, a reduction in systemic fluid retention will directly result in changes to body weight. These changes are a consequence of the drug's intended action to manage fluid balance.

Q: Is there a generic version or generic name available for Errolon A?

A: The active ingredients in Errolon A are established compounds: Amiloride and Furosemide. Official documentation confirms that these components are widely available in generic formulations as individual products or as combination products.

Q: How is the mechanism of action for Errolon A described compared to older medications for the same condition?

A: According to official product information, Errolon A is a combination medicine containing two distinct diuretics. This approach is designed to optimize fluid excretion (diuresis) while simultaneously working to conserve potassium. This dual mechanism helps mitigate the risk of severe potassium depletion, which is a key issue associated with some older, single-agent diuretics.

Q: Does Errolon A interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Regulatory documents indicate that the Furosemide component of Errolon A can interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. This combination may reduce the medicine's fluid-excreting effects and potentially increase the risk of kidney issues. There is no comparable specific warning for acetaminophen (Tylenol) in the official interaction profile.

Q: Are there any known interactions between Errolon A and caffeine or energy drinks?

A: Official information indicates that excessive caffeine intake may have an additive effect when combined with Errolon A. This is because caffeine is a natural diuretic. Combining the two could potentially enhance fluid excretion, raising the risk of dehydration and electrolyte imbalance.

Q: What is the effect of consuming alcohol while taking Errolon A?

A: Official documents warn that consuming alcohol may result in additive effects on lowering blood pressure. This combination can increase the risk of side effects like dizziness and fainting. These effects occur due to the combined action of alcohol and the diuretic's fluid-releasing effect.

Q: Are there specific food types or dietary restrictions to consider when using Errolon A?

A: Due to the risk of Hyperkalemia (high blood potassium), official safety information emphasizes the need to monitor intake of foods and supplements that contain potassium. Additionally, consuming excessive salt may weaken the intended fluid-releasing effects of the medicine.

Q: What is the typical timeframe before a patient can expect to notice the effects of Errolon A?

A: Regulatory pharmacokinetics data indicates that the onset of action for the Furosemide component is usually rapid, beginning within the first hour of taking the oral tablet. The peak effect of the medication is typically achieved within one to two hours after administration.

Q: Is it normal to feel slightly worse or experience temporary side effects when first starting Errolon A?

A: Official information lists common side effects such as headache, dizziness, and nausea, which may be more noticeable when treatment is initiated. While the severity can vary, any observed symptoms should be reported to a healthcare provider for evaluation.

Q: Are there any restrictions on taking Errolon A for people with diabetes or high blood pressure?

A: Official safety warnings note that the drug may make it harder to manage blood sugar levels (Hyperglycemia risk) in patients with diabetes. Individuals with high blood pressure are required to undergo close blood pressure monitoring when starting this treatment. These restrictions are due to the drug’s effects on metabolic and cardiovascular function.

Q: Is Errolon A classified as a controlled substance?

A: According to official sources, the active components of Errolon A are not subject to the Controlled Substances Act (CSA). Therefore, this medicine is not classified as a controlled substance in the regulatory framework.

Q: Is there a risk of physical dependence or withdrawal symptoms associated with Errolon A?

A: Regulatory documents do not contain warnings regarding physical dependence or addiction risk. The medicine is not a controlled substance, and its mechanism of action is focused on regulating fluid and electrolytes, which does not suggest a potential for addiction.

Q: What is the recommended guidance if a dose of Errolon A is accidentally missed?

A: Official regulatory instructions indicate that if a dose of Errolon A is missed, patients are advised to take the dose as soon as possible. However, if it is nearly time for the next scheduled dose, guidance is usually to skip the missed dose and continue with the regular schedule.

Q: What is the purpose of the black box warning (if any) that is included on the label for Errolon A?

A: The Furosemide component of the medicine carries a prominent Boxed Warning (sometimes called a Black Box Warning) from regulatory authorities. This warning highlights that the drug is a potent diuretic and that excessive use or dosage can lead to substantial loss of water and electrolytes. This extreme fluid loss can result in dehydration and electrolyte depletion.

Q: What do I need to know about the research evidence supporting the long-term effectiveness of Errolon A?

A: Official regulatory summaries cite evidence of the drug's effectiveness from Phase 3 clinical trials. These studies typically evaluate primary endpoints, such as disease activity changes, after a treatment duration of approximately 12 weeks.

Q: Has Errolon A been approved by regulatory bodies outside of the initial approval region (e.g., in Europe or Canada)?

A: Official product information has been issued by multiple regulatory bodies globally. These include the Health Products Regulatory Authority (HPRA) in the European Union and Medsafe in New Zealand, confirming its approval and regulatory oversight in various regions.

Q: Can I take multivitamins or mineral supplements while using Errolon A?

A: Regulatory warnings highlight the need for caution with supplements, particularly those containing high levels of potassium, due to the risk of Hyperkalemia. While multivitamins are not explicitly prohibited, co-administration with any mineral supplement requires careful monitoring to prevent electrolyte disturbances.

Q: Does Errolon A have an impact on a person’s ability to drive or operate machinery?

A: Due to known side effects such as dizziness, vertigo, and fatigue, the official label includes a clear cautionary note. Patients are advised to avoid driving or operating hazardous machinery until they have determined how the medicine affects their physical capabilities.

Q: How is the effectiveness of Errolon A monitored by doctors during follow-up appointments?

A: According to medical guidance, a doctor primarily monitors effectiveness by observing the reduction of symptoms related to fluid overload. This involves assessing the reduction of edema (swelling), tracking weight loss, and stabilizing blood pressure and urine output.

Q: Can Errolon A be taken with other prescription medications for the same condition?

A: Regulatory documents strictly contraindicate the use of Errolon A alongside other potassium-sparing agents due to the severe risk of high blood potassium (Hyperkalemia). Caution is advised with any other medication that affects fluid balance or blood pressure regulation.

Q: What if I experience a rare or unexpected symptom after starting Errolon A?

A: Official safety information recommends contacting a healthcare professional immediately to report any rare, unexpected, or serious symptoms after starting the medicine. Prompt reporting is essential for assessing safety and adjusting care.

Q: Is it possible for Errolon A to cause changes in mood or emotional state?

A: While official side effect lists do not specifically include 'mood changes,' regulatory labels report Central Nervous System (CNS) effects such as dizziness, drowsiness, and confusion. These side effects are related to brain function and could indirectly affect emotional or mental state.

Q: Does Errolon A affect blood sugar levels or cholesterol?

A: Regulatory documents explicitly state that the medicine carries a risk of metabolic abnormalities, including Hyperglycemia (elevated blood sugar) and Hyperuricemia. Official prescribing information does not generally contain specific data regarding the drug’s effects on cholesterol levels.

Q: Is the formulation of Errolon A (e.g., tablet, capsule) important for its effectiveness?

A: Official instructions specify that Errolon A is provided as an oral tablet and must be swallowed whole with liquid. This indicates that the specific tablet formulation is necessary for proper absorption, and altering the form (such as crushing) may interfere with the intended absorption and effectiveness.

Q: Are there warnings about taking Errolon A alongside herbal sedatives or sleep aids?

A: Official interaction warnings cover co-use with medications classified as Central Nervous System (CNS) Depressants. Herbal sedatives or sleep aids that act as CNS depressants could potentially lead to enhanced sedation and require careful patient monitoring.

Q: How does Errolon A affect the function of the immune system?

A: Some scientific literature, including research supported by regulatory bodies, has suggested that the Furosemide component may exhibit anti-inflammatory or immunosuppressive activity on certain cells. This is a complex pharmacological effect that is not often discussed in simplified patient labels.

Q: What is the meaning of the specific safety class (e.g., Category B, C) that Errolon A is assigned to?

A: The Furosemide component is sometimes cited under older classification systems, such as TGA Category C for pregnancy. This category generally indicates that the drug’s pharmacological effects have caused or may be suspected of causing harmful effects on the fetus or newborn, though these effects may be reversible.

How should Errolon A be stored and disposed of?

The storage and disposal of Errolon A (oral tablets) must strictly follow official regulatory instructions to ensure stability and safety.

Storage Requirements

Errolon A must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in the original container and the container must remain tightly closed.

  • Protection: Store the medicine where it is protected from light and moisture. Do not store above 30 C (86 F) and do not freeze the product.
  • Safety: Always keep Errolon A out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired tablets must be completed according to local regulations. Regulatory guidelines mandate that the tablets should not be flushed down a toilet or poured into a drain. Authorities advise utilizing official drug take-back programs when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Errolon A found in:

A-Z Index: